Actionable news
0
All posts from Actionable news
Actionable news in MDCO: The Medicines Company,

The Medicines: Investor Presentation December 1, 2015

The following excerpt is from the company's SEC filing.

Legal notices Forward-looking statements Statements contained in this presentation about The Medicines Company (the Company), the Companys products and product candidates, clinical trial results, regulatory submissions, indications, product launches, the Companys future financial and operating results, and future opportunities for the Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words believes," anticipates," plans," expects," intends," potential," estimates," outlook and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward looking statements, including the extent of the commercial success of our products; the Company's ability to develop its global operations and penetrate foreign markets; whether the Companys patent and other litigation is resolved in a timely and satisfactory manner; whether the results of preclinical studies or early clinical trials will be indicative of the results of later clinical trials; whether the Companys product candidates will advance in the clinical trials process on a timely basis or at all; whether the clinical trial results will warrant submission of applications for regulatory approval; whether the Company will make regulatory submissions for product candidates on a timely basis or at all; whether the Companys product candidates will receive approvals from regulatory agencies on a timely basis or at all; whether the Companys ongoing and planned commercial launches will be successful; whether physicians, patients and other key decision makers will accept clinical trial results, whether the Company successfully enters into strategic partnerships; and such other factors as are set forth in the risk factors detailed from time to time in the Companys periodic reports filed with the Securities and Exchange Commission (SEC) including, without limitation, the risk factors detailed in the Companys Form 10-Q filed with the SEC on November 9, 2015, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. All forward-looking statements are qualified in their entirety by this cautionary statement.

The Medicines Company Today Cardiovascular disease Infectious disease Surgery and perioperative

The Medicines Company Today Cardiovascular disease Infectious disease Surgery and perioperative 4 potential blockbuster product candidates

The Medicines Company Today Cardiovascular disease Infectious disease Surgery and perioperative Marketed/ Approved Phase III Proof of concept Discovery MDCO-PCSsc (formerly ALN-PCSsc) Carbavance® ABP-700 MDCO-216

The Medicines Company Today Cardiovascular disease Infectious disease Surgery and perioperative Marketed/ Approved Phase III Proof of concept Discovery MDCO-PCSsc Carbavance® ABP-700 MDCO-216 3 recent key launches

The Medicines Company Today Cardiovascular disease Infectious disease Surgery and perioperative Marketed/ Approved Phase III Proof of concept Discovery MDCO-PCSsc Carbavance® ABP-700 Kengreal IONSYS® Orbactiv® MDCO-216

Cardiovascular disease Infectious disease Surgery and perioperative Marketed/ Approved Kengreal Orbactiv® IONSYS® Angiomax® Minocin IV® Recothrom® Cleviprex® Raplixa Argatroban RTU Preveleak Phase III Carbavance® Proof of concept MDCO-PCSsc ABP-700 MDCO-216 Discovery BLI program The Medicines Company Today

The Medicines Company A unique and high-potential pipeline. Large, addressable markets with high differentiation Focused strategy and plan for efficient capital deployment Proven development track record 5 major development programs leading to 9 regulatory approvals in the last 16 months

Unlock shareholder value Identify sources of non-dilutive capital; divest non-core assets Optimize capital structure Prioritize investment in differentiated development assets that target large markets The Medicines Company Near-term value creation plan

Cardiovascular disease Infectious disease Surgery and perioperative Marketed/ Approved Phase III Carbavance® Proof of concept MDCO-PCSsc ABP-700 MDCO-216 Discovery 4 potential blockbuster product candidates

MDCO-PCSsc is an investigational agent not approved for commercial use in any market PCSK9 synthesis inhibitor through RNA interference In Phase II trials for treatment of hypercholesterolemia in patients who require additional LDL-C lowering Phase I data showed that a single, low volume subcutaneous injection of MDCO-PCSsc lowers LDL-C >50% for ~6 months Potential bi-annual dosing could align diagnostic and treatment cycle MDCO-PCSsc Summary

Decision resources, 2014CDC, 2014 Familial Hypercholesterolemia; US Census Data MDCO-PCSsc is an investigational agent not approved for commercial use in any market MDCO-PCSsc Estimated initial market opportunity1 ~74 million dyslipidemia patients in US, 2014 Initial population for PCSK9 inhibition is ~13 million patients Anticipated expansion after cardiovascular outcome trials Lipid lowering therapy ~43.1 M Primary Prevention ~19.2 M Secondary Prevention ~23.9 M High Risk (LDL-C >70%) ~7.82 M FH ~0.65M2 Statin intolerant ~4.4M

MDCO-PCSsc Phase 1 study results LDL-C...


More